Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 6/20 | 0.48 |
| ▸ | BRD2 | P25440 | 5/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225279 | 0.82 | BRD4 (0.46) | SMN1; SMN2KMT2ABRD4BRD2BRD3 | |
| SCHEMBL224343 | 0.82 | BRD4 (0.46) | SMN1; SMN2KMT2ABRD4BRD2BRD3 | |
| SCHEMBL224530 | 0.80 | BRD4 (0.47) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL225382 | 0.80 | BRD4 (0.45) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL223664 | 0.80 | BRD4 (0.47) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL222902 | 0.80 | LMNA (0.44) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL222992 | 0.80 | LMNA (0.59) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL5838210 | 0.78 | BRD4 (0.64) | BRD4BRD2BRD3 | |
| SCHEMBL5838204 | 0.78 | BRD4 (0.64) | BRD4BRD2BRD3 | |
| SCHEMBL5838215 | 0.78 | BRD4 (0.64) | BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415764-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | Kowa Company, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | SMN1; SMN2 2091/4885TSHR 806/4885LMNA 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.